Navigation Links
Test Drug Seen as Best Hope in Decades for Tackling Parkinson's

A drug tested on lab mice slows and may even halt the progress of Parkinson's, offering the brightest pharmacological hope in decades of rolling back this tragic disease, US researchers report on Sunday.

Isradipine, already licensed for treatment for high blood pressure, rejuvenated ageing dopamine cells, the brain cells whose death causes Parkinson's, they say.

The outcome among mice was so promising that the team now plan on conducting trials on human volunteers.

"Our hope is that this drug will protect dopamine neurons, so that if you began taking it early enough, you won't get Parkinson's disease, even if you were at risk," said lead researcher James Surmeier, professor of physiology at Northwestern University in Chicago.

"It would be like taking a baby aspirin every day to protect your heart." Parkinson's is an incurable, degenerative disease of the central nervous system that causes uncontrollable shaking, along with impaired speech and movement.

In approximately one third of cases it also results in dementia.

Estimates of its prevalence vary between 0.1 and 0.3 percent of the population, meaning that approximately one in 500 people contract the disease.

The cause is a loss of dopamine, a chemical messenger that helps direct movement.

The substance is provided in a part of the brain called the substantia nigra.

Most pacemaking neurons use sodium ions to produce a regular electrical signal.

But the new research unexpectedly found that dopamine cells, when they reached adulthood, start to depend more and more on calcium ions.

This discovery is important, because calcium ions are far more troublesome to control than their placid sodium counterparts: the cell uses up lots of energy, either to round up and sequester the calcium or pump it out.

As a result, the dopamine cells become stressed on reaching their calcium-addicted adulthoo d and die prematurely.

Surmeier's hunch was to try isradipine, a well-tolerated hypertension and stroke drug commercialised under the name of DynaCirc, which blocks the channels in the cell surface that admit calcium.

Tested on lab-dish cells and then on mice which had been genetically engineered to have Parkinson's, the team found that within a few hours of being exposed to the drug, the neurons reverted to their youth-like state, of using sodium.

This lowered the cells' stress level, making them less vulnerable to the toxins, still poorly understood, that kills them.

"They start acting like they're youngsters again," Northwestern quoted Surmeier as saying.

The study is published online on Sunday by Nature, the British science journal.

So far the work has only been carried out on animals, and more needs to be done to assess the drug's effect on humans.

But Surmeier voiced cautious hopes it could be the first treatment to prevent or slow the progression of this devastating disease.

The mainstay treatment for Parkinson's is L-DOPA, a drug that the brain converts into dopamine.

At first, L-DOPA has a seemingly miraculous effective on symptoms.

The problem, though, is that it becomes less and less effective as time wears on and the disease progresses.

That forces doctors to raise the dose of this drug, which induces unwanted side-effects, including spastic, jerky movements.

So, if isradipine can slow the death of dopamine neurons, the L-DOPA "honeymoon" could be significantly extended.

"If we could double or triple the therapeutic window for L-DOPA, it would be a huge advance," said Surmeier.

"There has not been a major advance in the pharmacological management of Parkinson's in 30 years."


'"/>




Related medicine news :

1. Hope for First New Melanoma Treatment in Decades
2. Mentally Ill Man Spent Two Decades in Chains
3. Bubonic Plague Confirmed In L.A. After More Than Two Decades
4. Survivors of Childhood Polio Do Well Decades Later As They Age
5. Testosterone Levels in Men Decline Over Past Two Decades
6. Tackling Prostate Cancer With A New Dietary Supplement
7. Ways Of Tackling Antibiotic Resistance
8. Tackling Drug Addition in UK
9. Tackling of Cannabis Addiction
10. Heart Disease Can Be Avoided By Tackling The Cholesterol Early
11. WHO Praises Singapore and Vietnam but Slams China With Respect To Tackling SARS
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/21/2017)... , ... January 21, 2017 , ... In the United ... individuals experience the freedom of recovery, they often feel shame for having struggled with ... stress disorder (PTSD). In the workshop, “Rising Strong in Life After an Eating Disorder” ...
(Date:1/20/2017)... ... ... Hawkins, Pastor and Overseer at The House of Yahweh has posted a new publication this ... generation is a time like no other and society needs to understand the only way ... does not want to sound like an old bible beater because religion has a bad ...
(Date:1/20/2017)... ... January 20, 2017 , ... Lice Troopers, the lice removal company based ... school-aged children since the holiday season. , “It happens every year around this ... hugs and taking photos, which is the head-to-head gateway that lice need to spread.” ...
(Date:1/20/2017)... Aliso Viejo, California (PRWEB) , ... January 20, 2017 , ... ... and easy to use inside of Final Cut Pro X," said Christina Austin - ... filmed on the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and ...
(Date:1/20/2017)... ... , ... “Code Word: Chocolate Biscuit”: a biographical account following a man who went on to ... published author, Marlyn Ivey, born in Lynn Haven, Florida and at the age of 5, ... years of age, he joined the Navy and got married right out of boot camp. ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... 2017 Research and Markets has announced ... ([CBC, HGB/HCT, BMP, BUN Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic ... Forecasts, 2013 - 2024" report to their offering. ... The global clinical laboratory ... Introduction of innovative solutions on the grounds of maximum ...
(Date:1/20/2017)... Research and Markets has announced the addition of the ... to their offering. ... This research service on the global pharmaceutical stability testing market ... of the key participants in the market. The ... 2020. The market is expected to grow at a CAGR of ...
(Date:1/20/2017)... January 20, 2017 Avillion LLP, a co-developer ... Mark Weinberg , MD MBA as Chief Medical Officer. Dr ... USA . ... Dr Weinberg has spent more than 17 years as a ... companies to micro-cap biotech. Over the course of his career, he ...
Breaking Medicine Technology: